Improving eye treatment for herpes simplex virus infections using adefovir dipivoxil
Repurposing and reformulation of adefovir dipivoxil for improved topical treatment of herpes simplex virus infection of the eye
['FUNDING_R01'] · UNIVERSITY OF ARIZONA · NIH-10902619
This study is looking at a new way to treat herpes simplex virus keratitis, which can cause serious eye problems, by using a medication called adefovir dipivoxil in a form that’s easier to use and needs to be applied less often, making it better for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ARIZONA (nih funded) |
| Locations | 1 site (TUCSON, UNITED STATES) |
| Trial ID | NIH-10902619 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the treatment of herpes simplex virus keratitis, a leading cause of blindness due to corneal infections. The study aims to repurpose adefovir dipivoxil, an existing antiviral medication, to create a more effective topical treatment that requires less frequent application than current therapies. By investigating the optimal formulation and dosing schedule, the research seeks to improve patient adherence and therapeutic outcomes. The approach includes testing the drug's effectiveness in a controlled setting to ensure it is both safe and potent against the virus.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with herpes simplex virus keratitis who require topical antiviral treatment.
Not a fit: Patients with other types of eye infections or those who do not have herpes simplex virus keratitis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and user-friendly treatment for patients suffering from ocular herpes infections, potentially reducing the risk of blindness.
How similar studies have performed: Previous research has shown promise in repurposing existing antiviral medications for improved efficacy, suggesting that this approach could yield beneficial results.
Where this research is happening
TUCSON, UNITED STATES
- UNIVERSITY OF ARIZONA — TUCSON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DATE, ABHIJIT A — UNIVERSITY OF ARIZONA
- Study coordinator: DATE, ABHIJIT A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.